Hypoactive Sexual Desire Disorder (HSDD) Treatment Market 2019-2027 – Credence Research | Industry Size, Share & Forecast

Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Is Expected To Expand At A CAGR of 5.2%

SAN JOSE, United States - August 14, 2019 /MarketersMedia/ —

The latest market report published by Credence Research, Inc. “Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market - Growth, Future Prospects, Competitive Analysis, 2019- 2027,” the global hypoactive sexual desire disorder (HSDD) treatment market is set to expand at a CAGR of 5.2% from 2019 to 2027.

Browse the full report Hypoactive Sexual Desire Disorder (HSDD) Treatment Market - Growth, Future Prospects, Competitive Analysis 2019 – 2027 at https://www.credenceresearch.com/report/hypoactive-sexual-desire-disorder-hsdd-treatment-market

Market Insights

Hypoactive sexual desire disorder (HSDD) is currently on a rise in adult women population manifested by low self confidence and less connected with their partners. Recent approval of Vyleesi will provide essential momentum for the HSDD market growth. Currently 2 drugs such as BP101 and Prasterone 6.5 mg vaginal insert are under phase 3 clinical trial are being investigated for its safety and efficacy for treatment of HSDD.

Hypoactive sexual desire disorder is the most common type of sexual dysfunction occurring in adult women worldwide manifested by lack of sex interest for a period of six months or more due to personal distress or fluctuating sex hormones during the menstrual cycle. Accurate diagnosis of the symptoms manifested in hypoactive sexual desire disorder (HSDD) is very critical to finalize the treatment regimen which is either psychotherapy or pharmacotherapy. The PLISSIT model (Permission, Limited Information, Specific Suggestions and Intensive Therapy) aids in initial screening of HSDD. Psychotherapy is suggested to patients showing positive response to counseling sessions with sex therapist.

Request Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Research Sample: https://www.credenceresearch.com/sample-request/59843

Pharmacotherapy comprises of buspirone and bupropion off label treatment for HSDD in women suffering with low libido associated with anxiety and depression. Testosterone transdermal patches are used as an off label treatment in premenopausal and postmenopausal women with HSDD. Flibanserin is currently the only drug approved by USFDA for treating HSDD in premenopausal women owing to its multifunctional serotonin agonist and antagonist pharmacodynamic profile.

North America is the largest regional segment in the hypoactive sexual desire disorder (HSDD) treatment market representing a market share of 38.5%. The chief attributing factors responsible for its supreme market growth are growing incidence of low libido in the female population owing to increasing stress in daily life and fluctuating sex hormones during the menstrual cycle. Domicile of key players such as AMAG Pharmaceutcials, Allergan, Plc., S1 Biopharma, Inc. and Sprout Pharmaceuticals, Inc. further propel the market growth in North America regional segment. Europe is placed in the second position with a market share of 32.4% primarily due to affordable reimbursement scenario for the medicines prescribed for the treatment of hypoactive sexual desire disorder (HSDD). Asia Pacific holding a market share of 15.2% will be growing at a rapid pace during the forecast period owing to rising prevalence of HSDD in working women population and developing healthcare infrastructure.

Pharmaceutical companies providing pharmacotherapy for treating hypoactive sexual desire disorder are AMAG Pharmaceutcials, Allergan, Plc., Ivix, LLX., EndoCeutics, Inc., Emotional Brain BV., S1 Biopharma, Inc. and Sprout Pharmaceutcials, Inc.

Key Market Movements:

Growing incidence of low sex drive in women population worldwide
Affordable reimbursement scenario for pharmacotherapy employed in the treatment of HSDD
Recent approval of Vyleesi and strong product pipeline will further propel the HSDD market growth during the forecast period

Request Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Research Sample: https://www.credenceresearch.com/sample-request/59843

TOC:

1. Preface...

2. Executive Summary...

3. Hypoactive Sexual Desire Disorder Treatment Market: Dynamics and Future Outlook...

Chapter 4. Global Hypoactive Sexual Desire Disorder Treatment Market, by Therapy
4.1. Overview
4.2. Buspirone
4.3. Bupropion
4.4. Testosterone
4.5. Flibanserin
4.6. Bremelanotide
4.7. Cognitive Behavior Therapy
4.8. Pipeline Analysis
4.8.1. Phase III Drug
4.8.1.1. Prasterone 6.5 mg Vaginal Insert
4.8.1.2. BP101

Chapter 5. Global Hypoactive Sexual Desire Disorder Treatment Market, by Geography
5.1. Overview
5.2. North America Hypoactive Sexual Desire Disorder Treatment Market Analysis, 2017 – 2027
5.2.1. North America Hypoactive Sexual Desire Disorder Treatment Market, by Therapy, 2017 – 2027 (US$ Mn)
5.2.2. North America Hypoactive Sexual Desire Disorder Treatment Market, by Country, 2017 – 2027 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe Hypoactive Sexual Desire Disorder Treatment Market Analysis, 2017– 2027
5.3.1. Europe Hypoactive Sexual Desire Disorder Treatment Market, by Therapy, 2017 – 2027 (US$ Mn)
5.3.2. Europe Hypoactive Sexual Desire Disorder Treatment Market, by Country/Region, 2017 – 2027 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific Hypoactive Sexual Desire Disorder Treatment Market Analysis, 2017 – 2027
5.4.1. Asia Pacific Hypoactive Sexual Desire Disorder Treatment Market, by Therapy, 2017 – 2027 (US$ Mn)
5.4.2. Asia Pacific Hypoactive Sexual Desire Disorder Treatment Market, by Country/Region, 2017 – 2027 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of Asia Pacific...

Chapter 6. Company Profiles
6.1. AMAG Pharmaceuticals
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. News Coverage
6.2. Allergan, Plc.
6.3. Ivix LLX
6.4. EndoCeutics, Inc.
6.5. Emotional Brain BV ...

Browse the full report Hypoactive Sexual Desire Disorder (HSDD) Treatment Market - Growth, Future Prospects, Competitive Analysis 2019 – 2027 at https://www.credenceresearch.com/report/hypoactive-sexual-desire-disorder-hsdd-treatment-market

About Us:
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared to this task.

Contact Info:
Name: Chris Smith
Email: Send Email
Organization: Credence Research
Address: 105 N 1st ST #429, SAN JOSE, CA 95103 US
Phone: +18003618290
Website: https://www.credenceresearch.com

Source URL: https://marketersmedia.com/hypoactive-sexual-desire-disorder-hsdd-treatment-market-2019-2027-credence-research-industry-size-share-forecast/88908175

Source: MarketersMedia

Release ID: 88908175

More News From Daily Sports Club

Belgium forward Lukaku joins Inter Milan from Man United

Aug 22, 2019

MILAN — Inter Milan completed the signing of Belgium forward Romelu Lukaku from Manchester United on Thursday. Lukaku put pen to paper on a five-year deal with Inter, joining his younger brother in the Italian league. Jordan Lukaku plays for Serie A rival Lazio. No financial details were given, but Italian media reported that Inter paid United around 65 million euros ($73 million) plus 13 million euros ($15 million) in bonuses for the 26-year-old Lukaku. "Inter were the only club I wanted, because Inter is 'Not For Everyone.' I'm here to bring the Nerazzurri back to the top," Lukaku said....

Ronaldo returns to training at Juventus

Aug 22, 2019

TURIN, Italy — Cristiano Ronaldo has arrived back at Juventus for his first day of pre-season training. The 34-year-old Ronaldo was greeted by more than 100 fans Saturday on his arrival for standard medical tests. The fans shouted his name as well as chanting for him to win the Champions League for them as a smiling Ronaldo signed autographs and posed for selfies. Ronaldo will train for the first time under new Juventus coach Maurizio Sarri later Saturday. Ronaldo was signed from Real Madrid just over a year ago in the hope that the five-time World Player of the Year...

Teunissen wins Tour opening stage, Thomas crashes at end

Aug 22, 2019

BRUSSELS — Mike Teunissen claimed the first yellow jersey of this year's Tour de France with a sprint victory in Saturday's opening stage, which was marked by defending champion Geraint Thomas' crash in the finale. Thomas' Ineos team said he fell in the final meters but "feels fine." Another top contender, Jakob Fuglsang, also hit the tarmac about 20 kilometers (12 miles) from the finish in a separate crash. The 26-year-old Teunissen, who became the first Dutch rider to wear the yellow jersey since Erik Breukink 30 years ago, edged former world champion Peter Sagan and Caleb Ewan on the...

Cavendish's Tour de France omission creates internal rift

Aug 22, 2019

BRUSSELS — Mark Cavendish's omission from the Tour de France is creating a rift within his Dimension Data team. Team principal Doug Ryder insisted on Saturday at the start of the Tour's opening stage he made the right decision by leaving the 34-year-old sprinter at home, a move that left head of performance Rolf Aldag puzzled. Cavendish, who has 30 stage wins on the Tour, has not produced a single win this season while struggling to recover from the Epstein-Barr virus, but hoped he could get back in contention at cycling's marquee race. "Mark is a legend of the race....

Cycling's new generation ready to deliver at Tour de France

Aug 22, 2019

BRUSSELS — No matter who wins, this year's Tour de France will see a changing of the guard. And if the names of Wout Van Aert, Kasper Asgreen, Enric Mas or Caleb Ewan don't ring a bell now, they might soon be on everybody's lips. In the absence of many stalwart riders who have stamped their mark on cycling's marquee event in recent years, new faces will emerge this summer. There is a long list of top riders missing the Tour, which starts on Saturday from Brussels with a 194.5 kilometer (120.8-mile) stage through Flanders and back to the Belgian...

Search

About Us

From transfer news, tactical analysis to predictions, get only the best of the world of sports daily with Daily Sports Club.

Contact us: sales[at]dailysportsclub.com

Subscribe Now!